UCB

Belgium's UCB hit with FDA Form 483 after April inspection

UCB Pharma has been slapped with a Form 483 from the FDA following an inspection that uncovered multiple issues.

Joseph Keenan May 30, 2023 9:40am

Tschudin

Novartis targets new fields—and CAR-T—for immunology growth

May 10, 2023 5:00pm

Evenity

Kansas company sues Amgen for alleged infringement with Evenity

Apr 25, 2023 2:46pm

Wooden judge gavel with a blurred brass scale of justice behind

UCB's second shot at Neupro patent validation fails on appeal

Apr 13, 2023 11:51am

head to head against clash football helmets fight combat

Novartis, UCB set to battle it out in inflammatory skin disease

Apr 10, 2023 4:40pm

UCB touts new data for bimekizumab in hidradenitis suppurativa

Mar 20, 2023 3:05pm